title: Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells.
abstract: Osteosarcoma is the most common type of malignant bone cancer, accounting for 35% of primary bone malignancies. Because cancer cells utilize glucose as their primary energy substrate, the expression and regulation of glucose transporters (GLUT) may be important in tumor development and progression. GLUT expression has not been studied previously in human osteosarcoma cell lines. Furthermore, although insulin and insulin-like growth factor (IGF-I) play an important role in cell proliferation and tumor progression, the role of these hormones on GLUT expression and glucose uptake, and their possible relation to osteosarcoma, have also not been studied. We determined the effect of insulin and IGF-I on GLUT expression and glucose transport in three well-characterized human osteosarcoma cell lines (MG-63, SaOs-2, and U2-Os) using immunocytochemical, RT-PCR and functional kinetic analyses. Furthermore we also studied GLUT isoform expression in osteosarcoma primary tumors and metastases by in situ hybridization and immunohistochemical analyses. RT-PCR and immunostaining show that GLUT1 is the main isoform expressed in the cell lines and tissues studied, respectively. Immunocytochemical analysis shows that although insulin does not affect levels of GLUT1 expression it does induce a translocation of the transporter to the plasma membrane. This translocation is associated with increased transport of glucose into the cell. GLUT1 is the main glucose transporter expressed in osteosarcoma, furthermore, this transporter is regulated by insulin in human MG-63 cells. One possible mechanism through which insulin is involved in cancer progression is by increasing the amount of glucose available to the cancer cell.
authors.affiliation: CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Departamento de Biología Celular, Genética y Fisiología, Universidad de Málaga, Málaga, España.
authors.forename: Manuel
authors.initials: M
authors.lastname: Cifuentes
authors.forename: Maria A
authors.initials: MA
authors.lastname: García
authors.forename: Pilar M
authors.initials: PM
authors.lastname: Arrabal
authors.forename: Fernando
authors.initials: F
authors.lastname: Martínez
authors.forename: María J
authors.initials: MJ
authors.lastname: Yañez
authors.forename: Nery
authors.initials: N
authors.lastname: Jara
authors.forename: Bernardo
authors.initials: B
authors.lastname: Weil
authors.forename: Dolores
authors.initials: D
authors.lastname: Domínguez
authors.forename: Rodolfo A
authors.initials: RA
authors.lastname: Medina
authors.forename: Francisco
authors.initials: F
authors.lastname: Nualart
mesh_terms: D001692:Biological Transport / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002648:Child; D003847:Deoxyglucose / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D051272:Glucose Transporter Type 1 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007328:Insulin / Q000494:pharmacology*; D007700:Kinetics; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: D051272:Glucose Transporter Type 1; D007328:Insulin; D020033:Protein Isoforms; D012333:RNA, Messenger; C495677:SLC2A1 protein, human; D003847:Deoxyglucose; D005947:Glucose